EP1329520B1 - Probe for diagnosing infectious disease arising from Staphylococcus aureus - Google Patents

Probe for diagnosing infectious disease arising from Staphylococcus aureus Download PDF

Info

Publication number
EP1329520B1
EP1329520B1 EP03075759A EP03075759A EP1329520B1 EP 1329520 B1 EP1329520 B1 EP 1329520B1 EP 03075759 A EP03075759 A EP 03075759A EP 03075759 A EP03075759 A EP 03075759A EP 1329520 B1 EP1329520 B1 EP 1329520B1
Authority
EP
European Patent Office
Prior art keywords
dna
bacteria
probe
staphylococcus aureus
infectious diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP03075759A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1329520A2 (en
EP1329520A3 (en
Inventor
Akio Dr. Matsuhisa
Hirotsugu Dr. Uehara
Soji Eda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fuso Pharmaceutical Industries Ltd
Original Assignee
Fuso Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuso Pharmaceutical Industries Ltd filed Critical Fuso Pharmaceutical Industries Ltd
Publication of EP1329520A2 publication Critical patent/EP1329520A2/en
Publication of EP1329520A3 publication Critical patent/EP1329520A3/en
Application granted granted Critical
Publication of EP1329520B1 publication Critical patent/EP1329520B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Definitions

  • the present invention relates to probes, prepared by making use of causative bacteria of infectious diseases, which are useful for detecting and identifying the causative bacteria.
  • infection is defined as invasion and establishment of a foothold for growth in an organism by a pathogenic organism (hereinafter referred to as "bacteria"), then the outbreak of disease depends upon the interrelationship between the resistance of host and the virulence of bacteria.
  • bacteria pathogenic organism
  • bacteremia is not a disease caused by a particular bacterium, but is caused by emergence and habitancy of the various bacteria in blood, then onset thereof is clinically suspected when fever of about 40°C persists for two or more days. If a patient is an infant or is suffering from terminal cancer with weakened resistance, the patient may die in one or two days, therefore, the bacteremia is a serious and urgent disease, and the improvement in treatment methods thereof have been awaited.
  • phagocytes including neutrophils, monocytes and macrophages primarily work in defense of the body. Emergence of bacteria in the blood is thought as invasion of predominant bacteria which have emerged from the tissue of the phagocyte.
  • Bacteremia is a state wherein the bacteria is emerged into the blood, and a large amount of antibiotic is administrated to treat it wherein the causative bacteria is sensitive to the antibiotic.
  • antibiotics lower the functions of the internal organs such as liver, it is necessary to pay an attention to reduce an administration of an ineffective antibiotic to a patient in a serious state.
  • bacteremia When bacteremia is defined as a case wherein phagocytesis of cells can not overcome the virulence of bacteria, then the bacteria spread in the body through the blood, bacteremia with serious symptoms due to toxins produced by the bacteria is called as sepsis. Proof of sepsis, in the other word, establishment of the diagnosis requires a check on the items of 1) clinical symptoms, 2) culturing of specimen, 3) gram-staining of the bacteria contained in the specimen, and 4) shock state, then, upon completing the check of these items, the treatment method is determined. Accordingly, to quickly and reliably identify the bacteria have been awaited in the art.
  • Staphylococcus epidermides which is one of Staphylococci and is the causative bacterium of bacteremia, stayed in the skin of the normal person, then, there is a risk on contamination of a specimen with this bacterium when a needle is inserted into the skin.
  • the present practice depends on a treatment to be started when bacteremia is clinically suspected without awaiting the detection results, that is to say, a trial and error method wherein an antibiotic having broad spectrum is administrated first, and if the antibiotic is not effective after one or two day(s), another antibiotic will be tried.
  • the constituents of the living body are also stained together with bacteria, therefore, experience to quickly identify bacteria according to thier image through microscope is required, then there may be cases that can be hardly diagnosed as bacteremia.
  • bacteremia is a disease wherein a rapid and exact diagnosis have been required, the conventional diagnosis method can not respond to such requirements.
  • the present invention was established in view of the problems in the art, and is directed to a probe having a specific reactivity with DNA or RNA obtained from primary causative bacteria of the infectious diseases, then provide a genetic information by analyzing the base sequence of DNA in the probe.
  • a causative bacteria of the infectious diseases is detected rapidly and exactly, without cultivating/proliferating the bacteria, through a detection of DNA held in the causative bacteria digested and incorporated gradually with the phagocyte. Then, if primers are designed by referring to an information on base sequence of these probes, causative bacteria can identify, without the hybridization, by amplifying the DNA with PCR technique.
  • non-radioactive probe for example, biotinylated probe
  • biotinylated probe can be detected with an optical microscope in a conventional laboratory without radio isotope handling facilities, the detection process would be rapid and simple.
  • Blood collected from the patient who have been suffered with targeted diseases were applied to Blood Culture Method (BBC System: Blood Culture System; Roche) and to a conventional identification kit (Api 20, Apistaf, Apistlep 20: Bio-Meryu), and the each causative bacterium was isolated and identified according to the manual of said kit.
  • BBC System Blood Culture System; Roche
  • Apistaf, Apistlep 20 Bio-Meryu
  • Escherichia coli containing each clone prepared according to Manual of Maniatis (T. Maniatis, et al., "Molecular Cloning (A Laboratory Manual)", Cold Spring Harbour Laboratory (1982)) was cultivated with small scale culture, and obtained plasmids containing each clone.
  • Plasmids were digested with restriction enzyme HindIII, thereby inserts were separated completely from plasmids with 1% agarose-gel electrophoresis (Myupid: Cosmo-Bio), then, were transcribed to nylon membrane with Southern-Transfer Technique (Paul Biodine A: Paul), and were cross-hybridized with a probe prepared by labelling 32 P-dCTP (Amersham) through nick-translation to chromosome DNA from each bacteria species aforelisted.
  • a probe which did not cross-react with any insert except for a probe prepared from the origin species thereof was selected as a probe containing DNA fragment which is specific to causative bacteria of the infectious diseases.
  • each probe prepared from one of said three bacteria was designated as a probe for detecting all these bacteria as a relevant bacteria.
  • Probes (denotation) selected from each species through the foregoing methods are listed in the following Table 1.
  • Table 1 SPECIES DENOTATION Staphylococcus aureus SA-7, SA-24, SA-36, SA-77 Staphylococcus epidermidis SE-3, SE-22, SE-32, SE-37 Enterococcus faecalis S2-1, S2-3, S2-7, S2-27 Pseudomonas aeruginosa P2-2, P2-7, P2-17, P4-5 Escherichia coli EC-24, EC-34, EC-39, EC-625 Klebsiella pneumoniae KI-50 Enterobacter cloacae ET-12, ET-49
  • DNA of each clinical isolate were extracted according to the method of Example 1 (2), and samples for dot-blot-hybridization were obtained by spotting certain amount (e.g., 5 ⁇ l) of DNA to nylon filter and selecting the isolates denatured with alkaline.
  • Hybridization on DNA probes prepared from each subjected bacterium and labelled with biotin (Bio-dUTP; BRL) were performed overnignt according to Manual of Maniatis, supra, under the condition of 45% formamide, 5 ⁇ SSC, 42 °C.
  • each probe have reacted only with DNA obtained from origin strain (or relative strain thereof) and not reacted (hybridized) with any DNA obtained from strains except for strains from the origin strain, therefore, their specificity have been confirmed.
  • Escherichia coli K-12, JM109 transformants wherein the subcloned insert fragments (to be seqeuenced) is contained in pGem-3Z (Promega), was inoculated in 5ml of Luria-Bactani Medium (bacto-tryptone, 10g/lL; bacto-yeast extract, 5g/lL; NaCl, 10g/lL; adjusted pH to 7.0 with 5N NaOH) and cultivated overnight. Culture liquid was centrifuged (5, 000rpm, 5 min.) and collected the bacteria.
  • the precipitate was dissolved in 10 ⁇ l of distilled water, then 2 ⁇ l of fluorescent primer (0.42 A 260 unit/10ml, 4-6pmol) [M13 Universal Primer; 5'-Fluorescein-d[CGACGTTGTAAAACGACGGGCAGT]-3' (1.6pmol/ ⁇ l; 0.42 A 260 unit/ml); M13 Reverse Primer, 5'-Fluorescein-d[CAGGAAACAG CTATGAC]-3'(2.1 pmol/ ⁇ l; 0.42 A 260 unit/ml)] and 2 ⁇ l of saline for annealing were added thereto, and mixed gently.
  • samples were prepared by adding thereto 1 ⁇ l of an elongation saline and 3 ⁇ l of dimethyl sulfoxide.
  • T7DNA polymerase (Pharmacia; 6-8units/2 ⁇ l) was added to DNA sample, and completely mixed by pipetting or mixing it gently. Immediately after completing the mixing, these mixed solution was poured into 4.5 ⁇ l of four-types solution respectively which have kept the certain temperature. Fresh tips were used at the time of pouring.
  • the solution have been kept for five minutes at 37°C, then 5 ⁇ l of termination solution were poured into each reaction-solution. Fresh tips were used for pouring. Immediately after keeping the solution for 2-3 minutes at 90 °C, it was cooled on ice. 4-6 ⁇ l/lane of the solution was applied to the electrophoresis.
  • causative bacteria of the infectious diseases which have incorporated into the phagocyte can be directly detected, and rapidly and exactly identified without proliferating the bacteria. That is to say, according to the diagnosis using the probe of the present invention, identification of the bacteria can be realized with single specimen, then, reduced the necessary time for diagnosis to about one to two day(s), while the conventional method (with low detection rate) required 3-4 days, and improved remarkably the detection rate. Therefore, this invention can provide an objective factors for the treatment of bacteremia, then realize the effective treatment in the early stage of the infectious diseases, and expect to reduce the mortality.
  • these probes can be prepared artifically. Further, a part of information on the analyzed base sequences may be used for rapidly diagnosing the causative bacteria by amplifying DNA of causative bacteria of the infectious diseases in the clinical specimen with PCR technique and primers prepared by making use of said information.
  • Genomic DNA in the clinical specimen by comparing base sequences of Genomic DNA in the clinical specimen with that of the present invention, rapid identification of the species of the causative bacteria of infectious diseases can be realized.
  • the present invention provide desirable probes for diagnosing the infectious diseases, then expect utilities as a factor to prepare primers for PCR and standard sequence for a comparison with Genomic DNA in the clinical specimen, and further expect an effect to provide valuable hints for preparing and developing the other probes which specifically react with causative bacteria of the infectious diseases.
  • DNA obtained from the wild strains contain the mutated portion, apparently from the disclosure of the Examples above, said mutated DNA portion would not affects the utilities to be derived by the present invention comprising the specificity of the probes of the present invention in the hybridization for a diagnosis of the infectious diseases, and an usage of the information on the base sequences disclosed in the present application to design the primers for PCR technique to realize a rapid diagnosis of the infectious diseases.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP03075759A 1992-07-07 1993-07-07 Probe for diagnosing infectious disease arising from Staphylococcus aureus Expired - Lifetime EP1329520B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP17971992 1992-07-07
JP17971992 1992-07-07
EP93914968A EP0652291B1 (en) 1992-07-07 1993-07-07 Probe for diagnosing infectious disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP93914968A Division EP0652291B1 (en) 1992-07-07 1993-07-07 Probe for diagnosing infectious disease

Publications (3)

Publication Number Publication Date
EP1329520A2 EP1329520A2 (en) 2003-07-23
EP1329520A3 EP1329520A3 (en) 2003-12-17
EP1329520B1 true EP1329520B1 (en) 2006-11-29

Family

ID=16070679

Family Applications (10)

Application Number Title Priority Date Filing Date
EP01203326A Expired - Lifetime EP1160334B1 (en) 1992-07-07 1993-07-07 Probe for diagnosing infectious disease arising from Pseudomonas aeruginosa
EP03075758A Expired - Lifetime EP1329519B1 (en) 1992-07-07 1993-07-07 Probe for diagnosing infectious disease arising from Staphylococcus aureus
EP01203323A Expired - Lifetime EP1167543B1 (en) 1992-07-07 1993-07-07 Probe for diagnosing infectious disease arising from Staphylococcus epidermidis
EP04077305A Expired - Lifetime EP1498495B1 (en) 1992-07-07 1993-07-07 DNA probe specific for Staphylococcus epidermidis
EP04077306A Expired - Lifetime EP1498496B1 (en) 1992-07-07 1993-07-07 DNA probe specific for Staphylococcus epidermidis
EP93914968A Expired - Lifetime EP0652291B1 (en) 1992-07-07 1993-07-07 Probe for diagnosing infectious disease
EP03075757A Expired - Lifetime EP1329518B1 (en) 1992-07-07 1993-07-07 Probe for diagnosing infectious disease arising from Staphylococcus aureus
EP03075759A Expired - Lifetime EP1329520B1 (en) 1992-07-07 1993-07-07 Probe for diagnosing infectious disease arising from Staphylococcus aureus
EP01203324A Expired - Lifetime EP1167544B1 (en) 1992-07-07 1993-07-07 Probe for diagnosing infectious disease arising from Escherichia coli, Klebsiella pneumoniae or Enterobacter cloacae
EP01203321A Expired - Lifetime EP1167542B1 (en) 1992-07-07 1993-07-07 Probe for diagnosing infectious disease arising from Enterococcus faecalis

Family Applications Before (7)

Application Number Title Priority Date Filing Date
EP01203326A Expired - Lifetime EP1160334B1 (en) 1992-07-07 1993-07-07 Probe for diagnosing infectious disease arising from Pseudomonas aeruginosa
EP03075758A Expired - Lifetime EP1329519B1 (en) 1992-07-07 1993-07-07 Probe for diagnosing infectious disease arising from Staphylococcus aureus
EP01203323A Expired - Lifetime EP1167543B1 (en) 1992-07-07 1993-07-07 Probe for diagnosing infectious disease arising from Staphylococcus epidermidis
EP04077305A Expired - Lifetime EP1498495B1 (en) 1992-07-07 1993-07-07 DNA probe specific for Staphylococcus epidermidis
EP04077306A Expired - Lifetime EP1498496B1 (en) 1992-07-07 1993-07-07 DNA probe specific for Staphylococcus epidermidis
EP93914968A Expired - Lifetime EP0652291B1 (en) 1992-07-07 1993-07-07 Probe for diagnosing infectious disease
EP03075757A Expired - Lifetime EP1329518B1 (en) 1992-07-07 1993-07-07 Probe for diagnosing infectious disease arising from Staphylococcus aureus

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP01203324A Expired - Lifetime EP1167544B1 (en) 1992-07-07 1993-07-07 Probe for diagnosing infectious disease arising from Escherichia coli, Klebsiella pneumoniae or Enterobacter cloacae
EP01203321A Expired - Lifetime EP1167542B1 (en) 1992-07-07 1993-07-07 Probe for diagnosing infectious disease arising from Enterococcus faecalis

Country Status (11)

Country Link
US (5) US5807673A (ja)
EP (10) EP1160334B1 (ja)
JP (4) JP2798499B2 (ja)
KR (1) KR0159071B1 (ja)
AT (10) ATE307200T1 (ja)
AU (1) AU684250B2 (ja)
CA (1) CA2139847C (ja)
DE (10) DE69333958T2 (ja)
DK (8) DK1329519T3 (ja)
TW (1) TW256881B (ja)
WO (1) WO1994001583A1 (ja)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001564A (en) * 1994-09-12 1999-12-14 Infectio Diagnostic, Inc. Species specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial pathogens and associated antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories
US20020055101A1 (en) 1995-09-11 2002-05-09 Michel G. Bergeron Specific and universal probes and amplification primers to rapidly detect and identify common bacterial pathogens and antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories
JP3571378B2 (ja) * 1994-09-30 2004-09-29 扶桑薬品工業株式会社 感染症診断用プローブ
US6905670B2 (en) * 1995-03-28 2005-06-14 The General Hospital Corporation Methods of screening compounds useful for prevention of infection or pathogenicity
AUPN350795A0 (en) * 1995-06-13 1995-07-06 Australian National University, The Nucleic acid molecule and its uses in determining pathogenicity of Staphylococcus
US5994066A (en) * 1995-09-11 1999-11-30 Infectio Diagnostic, Inc. Species-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial pathogens and associated antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories
US6107071A (en) * 1996-09-24 2000-08-22 Smithkline Beecham Corporation Histidinol dehydrogenase
WO1998014563A1 (en) * 1996-09-30 1998-04-09 Smithkline Beecham Plc spsA POLYNUCLEOTIDES AND POLYPEPTIDES
US20100267012A1 (en) 1997-11-04 2010-10-21 Bergeron Michel G Highly conserved genes and their use to generate probes and primers for detection of microorganisms
US20030049636A1 (en) 1999-05-03 2003-03-13 Bergeron Michel G. Species-specific, genus-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial and fungal pathogens and associated antibiotic resistance genes from clinical specimens for diagnosis in microbiology laboratories
JP3520172B2 (ja) * 1997-03-25 2004-04-19 扶桑薬品工業株式会社 クレブシェラ・ニューモニエ菌に起因する感染症の診断用プローブ
CN1268178A (zh) * 1997-05-06 2000-09-27 人体基因组科学有限公司 粪肠球菌多核苷酸和多肽
US7060458B1 (en) * 1997-08-14 2006-06-13 Wyeth Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US6914131B1 (en) * 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
US6610836B1 (en) 1999-01-29 2003-08-26 Genome Therapeutics Corporation Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics
GB9911683D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
EP1246935B1 (en) 1999-09-28 2013-08-14 Geneohm Sciences Canada Inc. Highly conserved genes and their use to generate probes and primers for detection of microorganisms
KR100353506B1 (ko) * 1999-10-04 2002-09-19 제일제당주식회사 녹농균 동정 및 감염 진단용 프라이머
US6703492B1 (en) * 1999-11-09 2004-03-09 Smithkline Beecham Corporation Staphylococcus epidermidis nucleic acids and proteins
WO2001034809A2 (en) * 1999-11-09 2001-05-17 Glaxo Group Limited Staphylococcus epidermidis nucleic acids and proteins
EP1294931A4 (en) * 2000-02-25 2005-01-26 Gen Hospital Corp METHODS FOR DETECTING GRAM-POSITIVE ENTEROCOCCULAR VIRULENCE FACTORS
CN100473663C (zh) * 2000-02-28 2009-04-01 启龙股份公司 奈瑟球菌蛋白质的异源表达
US7078584B2 (en) * 2000-03-17 2006-07-18 The General Hospital Corporation Salmonella typhimurium-infected Caenorhabditis elegans for identifying inhibitors of infection
WO2001073038A2 (de) * 2000-03-31 2001-10-04 Lonza Ag Verfahren zur biotechnologischen herstellung von l-alaninol
US7112716B2 (en) * 2000-04-06 2006-09-26 The General Hospital Corporation Methods for screening and identifying host pathogen defense genes
CA2447750C (en) * 2001-05-31 2012-12-18 Fuso Pharmaceutical Industries, Ltd. Improved method for detecting and identifying causative microorganisms of infectious diseases
JPWO2002101037A1 (ja) * 2001-05-31 2005-04-07 扶桑薬品工業株式会社 食細胞機能の評価方法およびその利用
US20040161741A1 (en) 2001-06-30 2004-08-19 Elazar Rabani Novel compositions and processes for analyte detection, quantification and amplification
US6696254B2 (en) * 2001-11-21 2004-02-24 Kimberly-Clark Worldwide, Inc. Detection and identification of enteric bacteria
JP2004089046A (ja) * 2002-08-30 2004-03-25 Fuso Pharmaceutical Industries Ltd カンジダアルビカンス菌の検出用プローブおよびそれを用いた方法
JP2004313181A (ja) 2003-04-02 2004-11-11 Canon Inc 感染症起炎菌検出用プローブ及びプローブセット、ならびに担体及び遺伝子検査方法
US20090035767A1 (en) * 2006-11-28 2009-02-05 Canon Kabushiki Kaisha Primer for bacterium genome amplification reaction
US8017337B2 (en) * 2007-04-19 2011-09-13 Molecular Detection, Inc. Methods, compositions and kits for detection and analysis of antibiotic-resistant bacteria
WO2009152298A1 (en) * 2008-06-13 2009-12-17 Zeus Scientific, Inc. Methods, compositions and and diagnostic kits for the detection and treatment for staphylococcal nasal decolonization using achromopeptidase

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652517A (en) * 1984-06-11 1987-03-24 Diagnostic Research Limited Partnership Methods for the in vitro detection and identification of unknown pathogens or genetic entities
US5047334A (en) * 1987-06-30 1991-09-10 Repligen Corporation Novel prokaryotic expression and secretion system
US5004682A (en) * 1987-11-02 1991-04-02 Olin Corporation Method and kit for detecting live microorganisms in chlorine- or bromine-treated water
AU623889B2 (en) * 1988-04-20 1992-05-28 Fuso Yakuhin Kogyo Kabushiki Kaisha Method for diagnosis of infectious diseases and method of detecting and identifying microorganisms
JPH03501326A (ja) * 1988-06-20 1991-03-28 ルミニス・プロプライアタリー・リミテッド 血清型分類用ｄｎａプローブ
NL8900670A (nl) * 1989-03-17 1990-10-16 Stichting Tech Wetenschapp Polynucleotide-probe, werkwijze en kit voor het identificeren en opsporen van gram-negatieve bacterien.
EP0426837B1 (en) * 1989-05-23 1995-09-06 Amoco Corporation Nucleic acid probes for the detection of staphylococcus aureus
NL9002157A (nl) * 1989-11-27 1991-06-17 U Gene Research Bv Dna fragmenten en daarop gebaseerde dna-probes en primers.
ATE108209T1 (de) * 1990-02-10 1994-07-15 Nestle Sa Dns-sonde für lactobacillus helveticus.
AU8495291A (en) * 1990-09-14 1992-04-15 Chugai Seiyaku Kabushiki Kaisha Method of detecting mesitylene-cephem-resistant staphylococcus aureus

Also Published As

Publication number Publication date
JP2798499B2 (ja) 1998-09-17
EP1160334B1 (en) 2006-08-30
ATE326551T1 (de) 2006-06-15
EP1498495A2 (en) 2005-01-19
KR950702640A (ko) 1995-07-29
DK1498495T3 (da) 2006-10-09
DE69333008D1 (de) 2003-07-03
DK1329518T3 (da) 2006-12-27
EP1498495B1 (en) 2006-05-31
US5770375A (en) 1998-06-23
DE69334028T2 (de) 2007-05-10
DE69334018T2 (de) 2006-11-09
EP1167544A2 (en) 2002-01-02
DE69334060T2 (de) 2007-03-01
DK1329519T3 (da) 2006-05-08
JPH10304895A (ja) 1998-11-17
DK1160334T3 (da) 2007-01-08
US5763188A (en) 1998-06-09
EP1498496A2 (en) 2005-01-19
EP1167543A3 (en) 2004-01-07
EP1329519B1 (en) 2005-12-28
US5807673A (en) 1998-09-15
DK0652291T3 (da) 2003-06-23
ATE314467T1 (de) 2006-01-15
ATE346167T1 (de) 2006-12-15
ATE328118T1 (de) 2006-06-15
DE69334090D1 (de) 2007-01-04
EP1329518B1 (en) 2006-11-22
EP1167543A2 (en) 2002-01-02
EP1160334A3 (en) 2004-01-02
ATE338141T1 (de) 2006-09-15
EP1329520A2 (en) 2003-07-23
JPH10304897A (ja) 1998-11-17
DE69334080T2 (de) 2007-05-24
ATE346956T1 (de) 2006-12-15
DE69333887D1 (de) 2006-03-02
DE69334060D1 (de) 2006-10-12
EP1329518A2 (en) 2003-07-23
EP1498496B1 (en) 2006-05-17
TW256881B (ja) 1995-09-11
EP0652291A4 (en) 1999-08-18
EP1160334A2 (en) 2001-12-05
DK1329520T3 (da) 2006-12-27
DK1167542T3 (da) 2006-12-04
EP1498496A3 (en) 2005-03-09
DE69333008T2 (de) 2004-02-05
EP1167543B1 (en) 2005-10-19
CA2139847A1 (en) 1994-01-20
DE69334090T2 (de) 2007-05-10
EP1329519A2 (en) 2003-07-23
EP1167542B1 (en) 2006-11-02
EP1329520A3 (en) 2003-12-17
DK1498496T3 (da) 2006-09-18
EP1498495A3 (en) 2005-03-09
EP1167544A3 (en) 2004-03-03
DE69333887T2 (de) 2006-06-22
EP0652291A1 (en) 1995-05-10
EP1329518A3 (en) 2003-12-10
ATE344333T1 (de) 2006-11-15
CA2139847C (en) 2002-05-21
DE69333872T2 (de) 2006-06-14
ATE241702T1 (de) 2003-06-15
US5853998A (en) 1998-12-29
DE69333958T2 (de) 2006-08-03
DE69333872D1 (de) 2005-10-20
AU4513593A (en) 1994-01-31
JP2965544B2 (ja) 1999-10-18
AU684250B2 (en) 1997-12-11
JPH10304896A (ja) 1998-11-17
WO1994001583A1 (en) 1994-01-20
DE69334080D1 (de) 2006-12-14
EP0652291B1 (en) 2003-05-28
ATE307200T1 (de) 2005-11-15
EP1167542A3 (en) 2003-12-17
DE69334028D1 (de) 2006-07-06
DE69334018D1 (de) 2006-06-22
EP1167542A2 (en) 2002-01-02
JP3026789B2 (ja) 2000-03-27
KR0159071B1 (ko) 1998-11-16
US5798211A (en) 1998-08-25
DE69334094D1 (de) 2007-01-11
EP1167544B1 (en) 2005-09-14
ATE304609T1 (de) 2005-09-15
EP1329519A3 (en) 2004-01-07
JP2965543B2 (ja) 1999-10-18
DE69334094T2 (de) 2007-05-16
DE69333958D1 (de) 2006-02-02

Similar Documents

Publication Publication Date Title
EP1329520B1 (en) Probe for diagnosing infectious disease arising from Staphylococcus aureus
EP0670373B1 (en) Probe for diagnosing candida-infections
EP0785277B1 (en) Probe for diagnosing infectious diseases
EP0974658B1 (en) Probes for the diagnosis of infections caused by streptococcus pyogenes
EP0972833B1 (en) Probes for the diagnosis of infections caused by klebsiella pneumoniae
US6265568B1 (en) Probes for the diagnosis of infections caused by bacteroides fragilis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030317

AC Divisional application: reference to earlier application

Ref document number: 0652291

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Designated state(s): AT BE CH DE DK FR GB IT LI NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK FR GB IT LI NL SE

17Q First examination report despatched

Effective date: 20040326

AKX Designation fees paid

Designated state(s): AT BE CH DE DK FR GB IT LI NL SE

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 0652291

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK FR GB IT LI NL SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: CH

Ref legal event code: NV

Representative=s name: TROESCH SCHEIDEGGER WERNER AG

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REF Corresponds to:

Ref document number: 69334094

Country of ref document: DE

Date of ref document: 20070111

Kind code of ref document: P

ET Fr: translation filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20070627

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20070718

Year of fee payment: 15

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20070830

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20070711

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20070704

Year of fee payment: 15

Ref country code: NL

Payment date: 20070703

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20071008

Year of fee payment: 15

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

EUG Se: european patent has lapsed
NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20090201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080707

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080731

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080708

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080731

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20120704

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20120719

Year of fee payment: 20

Ref country code: IT

Payment date: 20120713

Year of fee payment: 20

Ref country code: DE

Payment date: 20120704

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69334094

Country of ref document: DE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69334094

Country of ref document: DE

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20130706

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20130709

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20130706